Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02915835 · ClinicalTrials.gov registry record · Phase 2
Riociguat in Scleroderma Associated Digital Ulcers
A Phase 2 study, sponsored by Dinesh Khanna, MD, MS.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT02915835: Completed Phase 2 study, sponsored by Dinesh Khanna, MD, MS.
NCT02915835 is a Phase 2 study that has completed, run by Dinesh Khanna, MD, MS. The registered enrollment target is 17 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02915835, a Phase 2 study, has completed, sponsored by Dinesh Khanna, MD, MS.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The primary objective of this study is to provide preliminary data on the efficacy (digital ulcer net burden) and safety of riociguat administered 3 times daily (TID) in comparison to placebo in patients with scleroderma-associated digital ulcers
Primary Outcome
Digital ulcer net burden is defined as the total number of "active" and indeterminate digital ulcers at an assessment. Active ulcers are defined as having a denuded area with defined border and loss of epithelialization, loss of epidermis and dermis. An indeterminate ulcer is defined as denudation that could not be visualized and no other clinical features of activity. A healed ulcer has complete re-epithelialization.
Interventions
- DRUG Placebo
- DRUG Riociguat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-07-24 |
| Phase | Phase 2 |
What the finished NCT02915835 record still lists
NCT02915835 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02915835 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02915835 about?
NCT02915835 is a clinical study titled "Riociguat in Scleroderma Associated Digital Ulcers". The primary objective of this study is to provide preliminary data on the efficacy (digital ulcer net burden) and safety of riociguat administered 3 times daily (TID) in comparison to placebo in patients with scleroderma-associated digital ulcers
What is the current status of trial NCT02915835?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2016-09. Estimated completion is 2018-07-24.
What interventions are being tested in trial NCT02915835?
The interventions under investigation include: Placebo (DRUG), Riociguat (DRUG).
Who is sponsoring clinical trial NCT02915835?
This trial is sponsored by Dinesh Khanna, MD, MS, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02915835's enrollment target sits among peer trials
17 1903rd of 2000 higher than 93 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia